Until recently, therapeutic options for melanoma (outside of early excision for thin melanomas which have a good prognosis) have had little to offer in terms of survival but recent targeted therapies with BRAF inhibitor drugs for tumors with BRAF mutations have improved survival (3). This evidence concerns the gene BRAF and melanoma.